Related Experiment Video
Updated: Feb 8, 2026

Boldness, Aggression, and Shoaling Assays for Zebrafish Behavioral Syndromes
Published on: August 29, 2016
Pharmacological Therapy in Brugada Syndrome
Oholi Tovia Brodie1,2, Yoav Michowitz2, Bernard Belhassen2
1University of Miami Miller School of Medicine Miami, USA.
Abstract:
Brugada syndrome (BrS) is a cardiac disease caused by an inherited ion channelopathy associated with a propensity to develop ventricular fibrillation. Implantable cardioverter defibrillator implantation is recommended in BrS, based on the clinical presentation in the presence of diagnostic ECG criteria. Implantable cardioverter defibrillator implantation is not always indicated or sufficient in BrS, and is associated with a high device complication rate. Pharmacological therapy aimed at rebalancing the membrane action potential can prevent arrhythmogenesis in BrS. Quinidine, a class 1A antiarrhythmic drug with significant Ito blocking properties, is the most extensively used drug for the prevention of arrhythmias in BrS. The present review provides contemporary data gathered on all drugs effective in the therapy of BrS, and on ineffective or contraindicated antiarrhythmic drugs.
Related Concept Videos
Gene Therapy
Group Therapy
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction
Drug Abuse and Addiction: Pharmacological Phenomena

